The latest price target for OncoCyte (NASDAQ:OCX) was reported by Needham on November 13, 2024. The analyst firm set a price target for $4.25 expecting OCX to rise to within 12 months (a possible 64.09% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for OncoCyte (NASDAQ:OCX) was provided by Needham, and OncoCyte reiterated their buy rating.

There is no last upgrade for OncoCyte

The last downgrade for OncoCyte Corp happened on December 1, 2022 when Lake Street changed their price target from $3 to $0.5 for OncoCyte Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OncoCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OncoCyte was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest OncoCyte (OCX) rating was a reiterated with a price target of $4.25 to $4.25. The current price OncoCyte (OCX) is trading at is $2.59, which is out of the analyst’s predicted range.